Cargando…
Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation
The calcineurin inhibitor tacrolimus is included in most immunosuppressive protocols after liver transplantation. This retrospective, observational 24-month study investigated the tolerability of once-daily MeltDose(®) prolonged-release tacrolimus (LCPT) after switching from twice-daily immediate-re...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795274/ https://www.ncbi.nlm.nih.gov/pubmed/33396492 http://dx.doi.org/10.3390/jcm10010124 |
_version_ | 1783634406475300864 |
---|---|
author | Willuweit, Katharina Frey, Alexandra Hörster, Anne Saner, Fuat Herzer, Kerstin |
author_facet | Willuweit, Katharina Frey, Alexandra Hörster, Anne Saner, Fuat Herzer, Kerstin |
author_sort | Willuweit, Katharina |
collection | PubMed |
description | The calcineurin inhibitor tacrolimus is included in most immunosuppressive protocols after liver transplantation. This retrospective, observational 24-month study investigated the tolerability of once-daily MeltDose(®) prolonged-release tacrolimus (LCPT) after switching from twice-daily immediate-release tacrolimus (IR-Tac) in a real-world cohort of 150 patients with previous liver transplantation. No graft rejection or new safety signals were observed. Only 7.3% of patients discontinued LCPT due to side effects. In the overall patient population, median liver transaminases, total cholesterol, triglycerides, glucose, and HbA(1c) remained constant after switching to LCPT. Total cholesterol significantly decreased (p ≤ 0.002) in patients with initially elevated levels (>200 mg/dL). A total of 71.8% of 96 patients maintained a glomerular filtration rate > 60 mL/min/1.73 m(2) throughout the study, while 44.7% of patients were classified as fast metabolizers and 55.3% as slow metabolizers. Median daily tacrolimus dose could be reduced by 50% in fast metabolizers and by 30% in slow metabolizers, while trough levels were maintained in the target range (4–6 ng/mL). In conclusion, our observational study confirmed previous evidence of good overall tolerability and a favorable outcome for the patients after switching from IR-Tac to LCPT after liver transplantation. |
format | Online Article Text |
id | pubmed-7795274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77952742021-01-10 Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation Willuweit, Katharina Frey, Alexandra Hörster, Anne Saner, Fuat Herzer, Kerstin J Clin Med Article The calcineurin inhibitor tacrolimus is included in most immunosuppressive protocols after liver transplantation. This retrospective, observational 24-month study investigated the tolerability of once-daily MeltDose(®) prolonged-release tacrolimus (LCPT) after switching from twice-daily immediate-release tacrolimus (IR-Tac) in a real-world cohort of 150 patients with previous liver transplantation. No graft rejection or new safety signals were observed. Only 7.3% of patients discontinued LCPT due to side effects. In the overall patient population, median liver transaminases, total cholesterol, triglycerides, glucose, and HbA(1c) remained constant after switching to LCPT. Total cholesterol significantly decreased (p ≤ 0.002) in patients with initially elevated levels (>200 mg/dL). A total of 71.8% of 96 patients maintained a glomerular filtration rate > 60 mL/min/1.73 m(2) throughout the study, while 44.7% of patients were classified as fast metabolizers and 55.3% as slow metabolizers. Median daily tacrolimus dose could be reduced by 50% in fast metabolizers and by 30% in slow metabolizers, while trough levels were maintained in the target range (4–6 ng/mL). In conclusion, our observational study confirmed previous evidence of good overall tolerability and a favorable outcome for the patients after switching from IR-Tac to LCPT after liver transplantation. MDPI 2020-12-31 /pmc/articles/PMC7795274/ /pubmed/33396492 http://dx.doi.org/10.3390/jcm10010124 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Willuweit, Katharina Frey, Alexandra Hörster, Anne Saner, Fuat Herzer, Kerstin Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title | Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title_full | Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title_fullStr | Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title_full_unstemmed | Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title_short | Real-World Administration of Once-Daily MeltDose(®) Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation |
title_sort | real-world administration of once-daily meltdose(®) prolonged-release tacrolimus (lcpt) allows for dose reduction of tacrolimus and stabilizes graft function following liver transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795274/ https://www.ncbi.nlm.nih.gov/pubmed/33396492 http://dx.doi.org/10.3390/jcm10010124 |
work_keys_str_mv | AT willuweitkatharina realworldadministrationofoncedailymeltdoseprolongedreleasetacrolimuslcptallowsfordosereductionoftacrolimusandstabilizesgraftfunctionfollowinglivertransplantation AT freyalexandra realworldadministrationofoncedailymeltdoseprolongedreleasetacrolimuslcptallowsfordosereductionoftacrolimusandstabilizesgraftfunctionfollowinglivertransplantation AT horsteranne realworldadministrationofoncedailymeltdoseprolongedreleasetacrolimuslcptallowsfordosereductionoftacrolimusandstabilizesgraftfunctionfollowinglivertransplantation AT sanerfuat realworldadministrationofoncedailymeltdoseprolongedreleasetacrolimuslcptallowsfordosereductionoftacrolimusandstabilizesgraftfunctionfollowinglivertransplantation AT herzerkerstin realworldadministrationofoncedailymeltdoseprolongedreleasetacrolimuslcptallowsfordosereductionoftacrolimusandstabilizesgraftfunctionfollowinglivertransplantation |